SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
This Quarter Return
+10.3%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$2.65B
AUM Growth
+$2.65B
(+7.4%)
Cap. Flow
-$10.1M
Cap. Flow
% of AUM
-0.38%
Top 10 Holdings %
Top 10 Hldgs %
40.85%
Holding
111
New
10
Increased
29
Reduced
18
Closed
14
Top Buys
| 1 |
Coca-Cola
KO
|
$57.8M |
| 2 |
Dick's Sporting Goods
DKS
|
$51.5M |
| 3 |
GE HealthCare
GEHC
|
$39.4M |
| 4 |
Danaher
DHR
|
$31.8M |
| 5 |
GE Aerospace
GE
|
$28.2M |
Top Sells
| 1 |
Insmed
INSM
|
$126M |
| 2 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$92.5M |
| 3 |
Microsoft
MSFT
|
$40.4M |
| 4 |
United Airlines
UAL
|
$28.3M |
| 5 |
Chipotle Mexican Grill
CMG
|
$27.1M |
Sector Composition
| 1 | Healthcare | 61.21% |
| 2 | Technology | 12.36% |
| 3 | Consumer Discretionary | 7.05% |
| 4 | Financials | 6.14% |
| 5 | Communication Services | 5.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Capital One
COF
$142B
| $41.3M | 1.25% |
194,160
-51,062
| -21% | -$10.9M |
|
27
Ferguson
FERG
$45.9B
| $41.3M | 1.25% |
189,660
+59,736
| +46% | +$13M |
|
|
28
GE HealthCare
GEHC
$32.6B
| $39.4M | 1.19% |
+532,280
| New | +$39.4M |
|
29
Boston Scientific
BSX
$158B
| $38M | 1.14% |
353,561
+91,462
| +35% | +$9.82M |
|
30
Fulcrum Therapeutics
FULC
$347M
| $35M | 1.05% |
5,082,900
+15,506
| +0.3% | +$107K |
|
|
31
Danaher
DHR
$145B
| $34.5M | 1.04% |
174,700
+161,100
| +1,185% | +$31.8M |
|
32
Arcus Biosciences
RCUS
$1.15B
| $30M | 0.91% |
3,688,858
+1,127,954
| +44% | +$9.18M |
|
33
Tesla
TSLA
$1.06T
| $29.3M | 0.88% |
92,357
-29,659
| -24% | -$9.42M |
|
34
Aura Biosciences
AURA
$386M
| $27.4M | 0.83% |
4,372,884
+1,640,998
| +60% | +$10.3M |
|
|
35
Insmed
INSM
$30.7B
| $24M | 0.72% |
238,783
-1,253,600
| -84% | -$126M |
|
36
Datadog
DDOG
$46.4B
| $24M | 0.72% |
178,832
-4,399
| -2% | -$591K |
|
37
Mineralys Therapeutics
MLYS
$1.94B
| $23.6M | 0.71% |
1,744,492
+76,733
| +5% | +$1.04M |
|
38
UnitedHealth
UNH
$280B
| $21.2M | 0.64% |
68,000
+38,100
| +127% | +$11.9M |
|
39
Johnson & Johnson
JNJ
$428B
| $20.3M | 0.61% |
132,786
+23,400
| +21% | +$3.57M |
|
40
Biogen
BIIB
$20.2B
| $19.1M | 0.58% |
151,890
+31,154
| +26% | +$3.91M |
|
41
Compass Therapeutics
CMPX
$473M
| $18.6M | 0.56% |
+7,149,493
| New | +$18.6M |
|
42
Erasca
ERAS
$454M
| $18.4M | 0.56% |
14,502,004
+2,187,000
| +18% | +$2.78M |
|
43
Merck
MRK
$212B
| $17.4M | 0.52% |
219,178
+75,078
| +52% | +$5.94M |
|
44
Goldman Sachs
GS
$219B
| $17.1M | 0.51% |
24,108
-1,430
| -6% | -$1.01M |
|
|
PVLA
45
Palvella Therapeutics, Inc. Common Stock
PVLA
$577M
| $16.1M | 0.49% |
714,463
| – | – |
|
46
Pinterest
PINS
$24.7B
| $15.4M | 0.46% |
+430,025
| New | +$15.4M |
|
47
Abeona Therapeutics
ABEO
$348M
| $15.2M | 0.46% |
2,676,000
-1,009,503
| -27% | -$5.73M |
|
48
Monte Rosa Therapeutics
GLUE
$303M
| $15.2M | 0.46% |
3,360,000
+1,796,202
| +115% | +$8.1M |
|
49
Moderna
MRNA
$9.31B
| $14.3M | 0.43% |
517,163
| – | – |
|
50
Kymera Therapeutics
KYMR
$2.87B
| $12M | 0.36% |
+275,000
| New | +$12M |
|